Informations générales (source: ClinicalTrials.gov)
Contrast-Enhanced Ultrasound Ability in the Characterization of Ovarian Masses
Interventional
N/A
University Hospital, Tours (Voir sur ClinicalTrials)
septembre 2002
février 2009
29 juin 2024
This study intends to assess the ability of contrast-enhanced ultrasound in the detection
of benign and malignant ovarian masses compared to unenhanced ultrasound.
By using an intravascular contrast agent, this noninvasive and feasible imaging technique
will allow the investigators to define specific microcirculation patterns in 100 women
with ovarian lesions.
The intravascular contrast agent properties will be compared between benign and malignant
adnexal masses.
The final purpose of this ultrasonography is to allow the early detection of tumors and
to improve the characterization between benign and malignant lesions.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| University Hospital of Tours - 37044 - Tours - France | Henri Marret, PR | Contact (sur clinicalTrials) | |||
Critères
Femme
Inclusion Criteria:
- 18 years of age or older
- Patient with adnexal mass detected by ultrasound
- Any programmed surgery
- 18 years of age or older
- Patient with adnexal mass detected by ultrasound
- Any programmed surgery
- Any contraindication to surgery
- Injection of another contrast agent within 24 hours before the study examination
- Pregnancy, breastfeeding
- Patient known to have a coronary syndrome
- Unstable angina and myocardial infarction
- Acute cardiac failure, Class III/IV cardiac failure
- Severe rhythm disorders
- Acute endocarditis
- Prosthetic valves
- Patient previously having received an investigational drug within 30 days prior to
admission into this study